The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
An optimal therapeutic strategy for unresectable locally advanced pancreatic cancer (UR-LAPC) has not been established. This study investigated the therapeutic efficacy of chemoradiotherapy (CRT) following induction chemotherapy with gemcitabine plus nab-paclitaxel (GnP) (CRT group) compared with sy...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/18/4733 |
id |
doaj-5e5fb54b41d348f894cd35d80c17c146 |
---|---|
record_format |
Article |
spelling |
doaj-5e5fb54b41d348f894cd35d80c17c1462021-09-25T23:50:42ZengMDPI AGCancers2072-66942021-09-01134733473310.3390/cancers13184733The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic CancerRyoji Takada0Kenji Ikezawa1Kazuma Daiku2Shingo Maeda3Yutaro Abe4Makiko Urabe5Yugo Kai6Takuo Yamai7Nobuyasu Fukutake8Tasuku Nakabori9Hiroyuki Uehara10Reiko Ashida11Hirofumi Akita12Hidenori Takahashi13Teruki Teshima14Kazuyoshi Ohkawa15Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Surgery, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka 541-8567, JapanAn optimal therapeutic strategy for unresectable locally advanced pancreatic cancer (UR-LAPC) has not been established. This study investigated the therapeutic efficacy of chemoradiotherapy (CRT) following induction chemotherapy with gemcitabine plus nab-paclitaxel (GnP) (CRT group) compared with systemic chemotherapy alone (CTx group) in patients with UR-LAPC. This was a retrospective study of 63 consecutive patients with UR-LAPC treated at our department in a Japanese cancer referral center between February 2015 and July 2018. We excluded patients who underwent other regimens and those enrolled in another prospective study. The CRT group (<i>n</i> = 25) exhibited significantly better progression-free survival (PFS) and overall survival (OS) than the CTx group (<i>n</i> = 20, PFS 17.9 vs. 7.6 months, <i>p</i> = 0.044; OS 29.2 vs. 17.4 months, <i>p</i> < 0.001). In the multivariate analyses, CRT following induction chemotherapy was identified as an independent prognostic factor for OS. Seven (15.6%) patients underwent conversion surgery, all of whom were in the CRT group. The R0 resection rate was 85.7% (6/7). In summary, patients with UR-LAPC experienced favorable treatment outcomes after receiving GnP as the first-line chemotherapy, especially when receiving additional CRT. Thus, this treatment strategy represents a promising treatment option for selected patients with UR-LAPC.https://www.mdpi.com/2072-6694/13/18/4733pancreatic ductal adenocarcinomachemoradiationinduction chemotherapyconversion surgerycombination chemotherapylocal response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ryoji Takada Kenji Ikezawa Kazuma Daiku Shingo Maeda Yutaro Abe Makiko Urabe Yugo Kai Takuo Yamai Nobuyasu Fukutake Tasuku Nakabori Hiroyuki Uehara Reiko Ashida Hirofumi Akita Hidenori Takahashi Teruki Teshima Kazuyoshi Ohkawa |
spellingShingle |
Ryoji Takada Kenji Ikezawa Kazuma Daiku Shingo Maeda Yutaro Abe Makiko Urabe Yugo Kai Takuo Yamai Nobuyasu Fukutake Tasuku Nakabori Hiroyuki Uehara Reiko Ashida Hirofumi Akita Hidenori Takahashi Teruki Teshima Kazuyoshi Ohkawa The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer Cancers pancreatic ductal adenocarcinoma chemoradiation induction chemotherapy conversion surgery combination chemotherapy local response |
author_facet |
Ryoji Takada Kenji Ikezawa Kazuma Daiku Shingo Maeda Yutaro Abe Makiko Urabe Yugo Kai Takuo Yamai Nobuyasu Fukutake Tasuku Nakabori Hiroyuki Uehara Reiko Ashida Hirofumi Akita Hidenori Takahashi Teruki Teshima Kazuyoshi Ohkawa |
author_sort |
Ryoji Takada |
title |
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer |
title_short |
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer |
title_full |
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer |
title_fullStr |
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer |
title_full_unstemmed |
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer |
title_sort |
survival benefit of chemoradiotherapy following induction chemotherapy with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-09-01 |
description |
An optimal therapeutic strategy for unresectable locally advanced pancreatic cancer (UR-LAPC) has not been established. This study investigated the therapeutic efficacy of chemoradiotherapy (CRT) following induction chemotherapy with gemcitabine plus nab-paclitaxel (GnP) (CRT group) compared with systemic chemotherapy alone (CTx group) in patients with UR-LAPC. This was a retrospective study of 63 consecutive patients with UR-LAPC treated at our department in a Japanese cancer referral center between February 2015 and July 2018. We excluded patients who underwent other regimens and those enrolled in another prospective study. The CRT group (<i>n</i> = 25) exhibited significantly better progression-free survival (PFS) and overall survival (OS) than the CTx group (<i>n</i> = 20, PFS 17.9 vs. 7.6 months, <i>p</i> = 0.044; OS 29.2 vs. 17.4 months, <i>p</i> < 0.001). In the multivariate analyses, CRT following induction chemotherapy was identified as an independent prognostic factor for OS. Seven (15.6%) patients underwent conversion surgery, all of whom were in the CRT group. The R0 resection rate was 85.7% (6/7). In summary, patients with UR-LAPC experienced favorable treatment outcomes after receiving GnP as the first-line chemotherapy, especially when receiving additional CRT. Thus, this treatment strategy represents a promising treatment option for selected patients with UR-LAPC. |
topic |
pancreatic ductal adenocarcinoma chemoradiation induction chemotherapy conversion surgery combination chemotherapy local response |
url |
https://www.mdpi.com/2072-6694/13/18/4733 |
work_keys_str_mv |
AT ryojitakada thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT kenjiikezawa thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT kazumadaiku thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT shingomaeda thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT yutaroabe thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT makikourabe thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT yugokai thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT takuoyamai thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT nobuyasufukutake thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT tasukunakabori thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT hiroyukiuehara thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT reikoashida thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT hirofumiakita thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT hidenoritakahashi thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT terukiteshima thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT kazuyoshiohkawa thesurvivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT ryojitakada survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT kenjiikezawa survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT kazumadaiku survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT shingomaeda survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT yutaroabe survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT makikourabe survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT yugokai survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT takuoyamai survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT nobuyasufukutake survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT tasukunakabori survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT hiroyukiuehara survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT reikoashida survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT hirofumiakita survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT hidenoritakahashi survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT terukiteshima survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer AT kazuyoshiohkawa survivalbenefitofchemoradiotherapyfollowinginductionchemotherapywithgemcitabineplusnabpaclitaxelforunresectablelocallyadvancedpancreaticcancer |
_version_ |
1717367751511638016 |